Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620776 · ClinicalTrials.gov registry record · Phase 2
Combined Treatment for Generalized Anxiety Disorder (GAD)
A Phase 2 study of Generalized Anxiety Disorder, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT00620776: Completed Phase 2 study of Generalized Anxiety Disorder, sponsored by University of Pennsylvania.
NCT00620776 is a Phase 2 study of Generalized Anxiety Disorder that has completed, run by University of Pennsylvania. The registered enrollment target is 69 participants, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620776, a Phase 2 study of Generalized Anxiety Disorder, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to conduct a preliminary evaluation of the efficacy of combined medication and psychotherapy for generalized anxiety disorder (GAD). The general goals of the current study are to conduct a late stage treatment development study. The goal of this stage of research is to provide a preliminary answer to the question and to gather data to estimate intervention parameters (e.g., effect size, attrition rates, response rates) that would assist in planning further research.
Primary Outcome
The HAM-A was used to measure the severity of anxiety symptoms. The scale consists of 14 items; each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate and 25-30 moderate to severe anxiety. This measure was conducted by research psychiatrists trained and highly experienced in the use of these scales. The evaluators were blind to group assignment.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy
- DRUG Venlafaxine XR
Study Locations (1)
Pennsylvania
- University of Pennsylvania, 3535 Market Street, Suite 650 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00620776 record still lists
NCT00620776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cognitive Behavioral Therapy is the first listed.
NCT00620776 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00620776 about?
NCT00620776 is a clinical study titled "Combined Treatment for Generalized Anxiety Disorder (GAD)". The purpose of this study is to conduct a preliminary evaluation of the efficacy of combined medication and psychotherapy for generalized anxiety disorder (GAD). The general goals of the current study are to conduct a late stage treatment development study. The goal of this stage of research is to p...
What is the current status of trial NCT00620776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2006-10. Estimated completion is 2008-03.
What conditions does trial NCT00620776 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00620776?
The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL), Venlafaxine XR (DRUG).
Who is sponsoring clinical trial NCT00620776?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00620776 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00620776's enrollment target sits among peer trials
69 33rd of 48 higher than 16 of 48 other Generalized Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Use of CBD in the Treatment of Anxiety
RECRUITING · Phase 2
-
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
RECRUITING · Phase 2
-
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
ACTIVE NOT RECRUITING · Phase 2
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia